Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Elixirium thymi compositum FoNo VIII is a standardized pharmaceutical preparation defined in the 8th edition of the Hungarian Formulae Normales (FoNo VIII). It is primarily indicated for the treatment of acute bronchitis and coughs requiring expectoration. The formulation typically contains fluid extract of thyme (Thymus vulgaris), ammonium chloride, and anise oil. Thyme extract provides secretolytic and bronchospasmolytic properties, primarily through its volatile oil components like thymol and carvacrol. Ammonium chloride acts as an expectorant by irritating the gastric mucosa, which reflexively increases bronchial secretions. Anise oil contributes additional secretolytic and mild antispasmodic effects. This combination is widely used in Hungarian clinical practice as a traditional cough remedy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Elixirium thymi compositum FoNo VIII.